https://www.noxopharm.com/site/PDF/2021_4/NOXReleasesLatestNewsletter
Noxopharm is aware of only two non-nucleotide STING agonists under development, intended to deliver a STING effect on a general basis but limited to cancer cells. One is the compound, MAVU-104, a pre-clinical drug candidate under development by Seattle-based Mavupharma.16 Mavupharma was acquired this week by Abbvie. The second drug candidate is Veyonda®.
Abbvie, a biopharmaceutical company with ~30,000 employees and a market cap of $102 Billion, paid an undisclosed sum for a pre-clinical compound.
Veyonda is already in the clinic and appears to selectively activate STING in humans - i.e. in cancer cells alone. I am happy to hold until someone comes knocking on our door.
Versatility Newsletter
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.06M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 11.5¢ | $5.653K | 48.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 22101 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 159073 | 5 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |